

IN THE CLAIMS:

1 1. (cancelled) A purified and isolated DNA molecule consisting essentially of the  
2 nucleotide sequence set forth in SEQ ID NO:1, or its complementary strand.

1 2. (cancelled) The purified and isolated DNA molecule of Claim 1, wherein said DNA  
2 molecule encodes for a purified and isolated protein molecule consisting essentially of the amino  
3 acid sequence set forth in SEQ ID NO:2.

1 3. (currently amended) A live, attenuated strain of *V. anguillarum* which comprises:

2 a <sup>mutated</sup> *mugA* gene comprising nucleotides 1218-2610 of SEQ ID NO:1, <sup>wherein said</sup> the strain  
3 <sup>mutation is located within nts of 1218-2610 of SEQ ID NO:1</sup> characterized in that it is the *mugA* gene being mutated such that the strain is incapable of  
4 expressing a functional *mugA* protein.

1 4. (original) The live, attenuated strain according to claim 3 wherein the strain is incapable  
2 of growing in salmon intestinal mucus.

1 5. (original) The live, attenuated strain according to claim 3 wherein the mutation is non-  
2 revertible.

1 6. (original) The live, attenuated strain according to claim 4 wherein the mutation is an  
2 insertion.

1 7. (original) The live, attenuated strain according to claim 4 wherein the mutation is a  
2 deletion.

1 8. (currently amended) A vaccine strain against *V.anguillarum* infection in an animal  
2 selected from the group consisting of fish, bivalves and crustaceans comprising:

3 a live, attenuated strain of *V.anguillarum*; ~~the strain comprised of a mutated *mugA* gene;~~  
4 ~~the strain characterized in that it is incapable of expressing a functional *mugA* protein which~~  
5 comprises a *mugA* gene comprising nucleotides 1218-2610 of SEQ ID NO:1, the *mugA* gene  
6 being mutated such that the strain is incapable of expressing a functional *mugA* protein.

1 9. (original) The vaccine strain according to claim 8 wherein the strain further comprises a  
2 pharmaceutically acceptable carrier.

1 10. (cancelled) The vaccine strain according to claim 8 wherein the animal is a fish.

1 11. (cancelled) The vaccine strain according to claim 8 wherein the animal is a bivalve.

1 12. (cancelled) The vaccine strain according to claim 8 wherein the animal is a crustacean.

1 13. (original) The vaccine strain according to claim 8 wherein the mutation is non-revertible.

1 14. (original) The vaccine strain according to claim 13 wherein the mutation is an insertion.

1 15. (original) The vaccine strain according to claim 13 wherein the mutation is a deletion.

1 16. (currently amended) A method for immunizing an animal selected from the group  
2 consisting of fish, bivalves and crustaceans against *V. anguillarum* infection in ~~an~~ the animal  
3 which comprises:

4 administering to the animal a vaccine comprised of a live, attenuated strain of  
5 *V.anguillarum*, ~~the strain comprised of a mutated *mugA* gene which comprises a mutated *mugA*~~  
6 ~~gene comprising nucleotides 1218-2610 of SEQ ID NO:1, the strain characterized in that it is the~~  
7 *mugA* gene being mutated such that the strain is incapable of expressing a functional *mugA*  
8 protein.

9 ~~the strain characterized in that it is incapable of expressing a functional *mugA* protein as a~~  
10 ~~result of the mutation in the *mugA* gene.~~

1 17. (original) The method according to claim 16 wherein administering comprises  
2 immersion.

1 18. (original) The method according to claim 16 wherein administering comprises  
2 intraperitoneal injection.

1 19. (original) The method according to claim 16 wherein administering comprises oral  
2 intubation.

1 20. (original) The method according to claim 16 wherein administering comprises anal  
2 intubation.

1 21. (original) The method according to claim 16 wherein administering comprising  
2 immersing the animal in a medium containing the attenuated strain.

---

1 22. (canceled) The method according to claim 16 wherein the animal is a fish.

1 23. (canceled) The method according to claim 16 wherein the animal is a bivalve.

1 24. (canceled) The method according to claim 16 wherein the animal is a crustacean.

1 25. (original) The method according to claim 16 wherein the mutation in the *mugA* gene is  
2 non-revertible.

1 26. (original) The method according to claim 25 wherein the mutation in the *mugA* gene is  
2 an insertion.

1 27. (original) The method according to claim 25 wherein the mutation in the *mugA* gene is a  
2 deletion.

1 28. (currently amended) A method of inducing an immune response in an animal selected  
2 from the group consisting of fish, bivalves and crustaceans against one or more pathogens which  
3 comprises transforming a live, attenuated strain of *V. anguillarum* which comprises a *mugA* gene  
4 comprising nucleotides 1218-2610 of SEQ ID NO:1, the *mugA* gene being mutated such that the  
5 strain is incapable of expressing a functional *mugA* protein, the strain characterized in that it is  
6 incapable of expressing a functional *mugA* protein, with a plasmid comprising DNA of interest  
7 encoding at least one protein antigen for each of the pathogens and administering the  
8 transformed strain to ~~an~~ the animal.

1 29. (canceled) A method for the detection of the presence of *V. anguillarum* in animal tissue  
2 or fluids comprising:

3 contacting the sample with a detectably labeled DNA probe wherein the probe comprises  
4 a detectable single-stranded DNA having a nucleotide sequence which specifically and

5 selectively hybridizes with DNA of *V. anguillarum*, the DNA probe comprising a nucleotide  
6 sequence selected from the group consisting of SEQ ID NO. 1, whereby the presence of the  
7 DNA is indicative of a *V. anguillarum* infection.

1 30. (new) A mutated strain of *V. anguillarum* characterized in that the strain is incapable of  
2 growing in salmon intestinal mucous.

Not  
necessary  
due to a  
muta-  
50